公开(公告)号：US10683321B2

公开(公告)日：2020-06-16

申请号：US15104706

申请日：2014-12-17

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： David Dukhan ,  Cyril B. Dousson ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistair James Stewart

IPC: C07H19/207 ,  C07H19/10 ,  C07H19/16 ,  C07H19/06 ,  C07H19/20 ,  A61P31/14

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4′-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.

公开(公告)号：US10519159B2

公开(公告)日：2019-12-31

申请号：US15847971

申请日：2017-12-20

Applicant: Merck Sharp & Dohme Corp. ,  Idenix Pharmaceuticals LLC

Inventor： Jean-Laurent Paparin ,  Izzat Raheem ,  Houcine Rahali ,  Daniel Da Costa ,  David Dukhan

IPC: C07D473/34 ,  A61K45/06 ,  A61P31/18 ,  A61K31/52 ,  A61K31/675 ,  C07F9/6561 ,  A61K9/00

Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

公开(公告)号：US20190233463A1

公开(公告)日：2019-08-01

申请号：US16311363

申请日：2017-06-20

Applicant: MERCK SHARP & DOHME CORP. ,  IDENIX PHARMACEUTICALS LLC

Inventor： Stephane BOGEN ,  David DUKHAN ,  Guillaume BRANDT ,  Claire Pierra ROUVIERE ,  Cyril B. DOUSSON ,  Francois-Rene ALEXANDRE

IPC: C07H19/213 ,  C07H19/11 ,  A61K31/7076 ,  A61K31/7072 ,  A61K45/06 ,  A61P31/14

CPC classification number: C07H19/213 ,  A61K31/7072 ,  A61K31/7076 ,  A61K45/06 ,  A61P31/14 ,  C07H19/11 ,  A61K2300/00

Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.

公开(公告)号：US10231986B2

公开(公告)日：2019-03-19

申请号：US14866759

申请日：2015-09-25

Applicant: Centre National De La Recherche Scientifique ,  Universite Montpellier 2 Sciences Et Techniques ,  Idenix Pharmaceuticals LLC

Inventor： David Dukhan ,  Christophe Claude Parsy ,  Gilles Gosselin ,  Jean-François Griffon ,  Guillaume Brandt ,  Cyril B. Dousson ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistar James Stewart

IPC: C07H19/073 ,  C07H19/10 ,  C07H19/173 ,  C07H19/20 ,  A61K31/7072 ,  C07H17/02 ,  A61K31/7068 ,  A61K45/06 ,  A61K9/00 ,  A61K31/7076

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.

公开(公告)号：US10202411B2

公开(公告)日：2019-02-12

申请号：US15304506

申请日：2015-04-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： David Dukhan ,  Cyril B. Dousson ,  Gilles Gosselin ,  Jean-Laurent Paparin ,  Guillaume Brandt ,  Rachid Rahali ,  Aurelien Salanson ,  François-René Alexandre

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/20 ,  C07H19/10 ,  C07H19/11 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7064 ,  A61K31/708 ,  A61K31/7052 ,  A61K31/706

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

公开(公告)号：US20180235993A1

公开(公告)日：2018-08-23

申请号：US15952117

申请日：2018-04-12

Applicant: Idenix Pharmaceuticals LLC ,  Universita' degli Studi di Cagliari

Inventor： Jean-Pierre Sommadossi ,  Paolo La Colla

IPC: A61K31/7072 ,  C07H19/20 ,  A61K38/21 ,  A61K31/7052 ,  A61K31/7056 ,  C07H19/16 ,  A61K31/7076 ,  C07H19/23 ,  C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  A61K31/7064

CPC classification number: A61K31/7072 ,  A61K31/7052 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7076 ,  A61K38/21 ,  C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H19/23 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389

Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US10005779B2

公开(公告)日：2018-06-26

申请号：US14296122

申请日：2014-06-04

Applicant: Idenix Pharmaceuticals LLC

Inventor： David Dukhan ,  Gilles Gosselin ,  Cyril B. Dousson

IPC: C07D409/04 ,  C07D473/18 ,  A61K31/506 ,  A61K31/522 ,  A61K45/06 ,  C07H19/067

CPC classification number: C07D473/18 ,  A61K31/506 ,  A61K31/522 ,  A61K45/06 ,  C07D409/04 ,  C07H19/067

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 1′,4′-thio nucleoside compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof; wherein Base, RA, RB, W, X, Y, and Z are as described herein.

公开(公告)号：US20170135990A1

公开(公告)日：2017-05-18

申请号：US15122954

申请日：2015-03-04

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Adel M. Moussa ,  Benjamin Alexander Mayes ,  Sindhura Ganga

IPC: A61K31/4184 ,  A61K45/06 ,  A61K9/16

CPC classification number: A61K31/4184 ,  A61K9/16 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K45/06 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393

Abstract: Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also provided herein are pharmaceutical compositions comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, method of their preparation, and their use for treating or preventing hepatitis C virus infection.

公开(公告)号：US20160280729A1

公开(公告)日：2016-09-29

申请号：US15038255

申请日：2014-11-19

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Adel M. Moussa ,  Alistair James Stewart ,  Benjamin Alexander Mayes

IPC: C07F9/6512 ,  C07F9/6561 ,  A61K31/675 ,  A61K31/685 ,  A61K45/06

CPC classification number: C07F9/6512 ,  A61K31/675 ,  A61K31/685 ,  A61K45/06 ,  C07D239/47 ,  C07D239/54 ,  C07D239/553 ,  C07D471/04 ,  C07D473/16 ,  C07D473/18 ,  C07D473/34 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/65616

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Z1 Z2, Z3, Z4, V, W, X, Y, Ar, R1 and R2 are as described herein.